High-grade serous Ovarian Cancer: TP53 Mutations and Platinum Response

被引：0
|
作者：
Lorenz, Judith
机构：
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1055/a-2308-6206
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Up to 96% of High-grade serous Ovarian Cancers have Mutations of the Tumor Suppressor Gene TP53. This results in a Loss of Function or Dysfunction of the Protein p53, which plays an important Role in Regulating the Cell Cycle. A US Research Team has now investigated the oncogenic Potential of various TP53 Mutations with regard to clinical Treatment Outcomes and in particular the Development of Platinum Resistance.
引用
收藏
页数：1
相关论文
共 50 条
  • [41] TP53-wildtype High-Grade Serous Tubo-Ovarian Carcinomas
    Chui, M. Herman
    Soslow, Robert
    [J]. LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1029 - 1029
  • [42] TP53-wildtype High-Grade Serous Tubo-Ovarian Carcinomas
    Chui, M. Herman
    Soslow, Robert
    [J]. MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1029 - 1029
  • [43] The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
    Brachova, Pavla
    Thiel, Kristina W.
    Leslie, Kimberly K.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (09) : 19257 - 19275
  • [44] Correlation of p53 Immunohistochemical Expression with TP53 Mutation in Extrauterine High-Grade Serous Carcinoma
    Karim, Lina Abdul
    Yang, Richard
    Ramalingam, Preetha
    Lawson, Barrett
    Malpica, Anais
    [J]. MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 639 - 640
  • [45] Correlation of p53 Immunohistochemical Expression with TP53 Mutation in Extrauterine High-Grade Serous Carcinoma
    Karim, Lina Abdul
    Yang, Richard
    Ramalingam, Preetha
    Lawson, Barrett
    Malpica, Anais
    [J]. LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 639 - 640
  • [46] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22
  • [47] BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma
    McAlpine, Jessica N.
    Porter, Henry
    Koebel, Martin
    Nelson, Brad H.
    Prentice, Leah M.
    Kalloger, Steve E.
    Senz, Janine
    Milne, Katy
    Ding, Jiarui
    Shah, Sohrab P.
    Huntsman, David G.
    Gilks, C. Blake
    [J]. MODERN PATHOLOGY, 2012, 25 (05) : 740 - 750
  • [48] Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma
    Kim, Yong-Man
    Lee, Shin-Wha
    Lee, Young-Jae
    Lee, Ha-Young
    Lee, Jong-Eun
    Choi, Eun-Kyung
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (03)
  • [49] Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma
    Lee, Y. J.
    Kim, Y. M.
    Lee, S. W.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 270 - 270
  • [50] Most High Grade Serous Carcinomas Arising in Low Grade Serous Carcinomas Do Not Show Evidence of TP53 or BRAF Mutations
    Zarei, Shabnam
    Kerr, Sarah E.
    Wang, Yan
    Jenkins, Sarah M.
    Bell, Debra A.
    [J]. MODERN PATHOLOGY, 2016, 29 : 315A - 315A
12345